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PTEN regulates AMPA receptor-mediated cell viability
in iPS-derived motor neurons
D-J Yang1,3, X-L Wang1,3, A Ismail2, CJ Ashman2, CF Valori2,4, G Wang1, S Gao1, A Higginbottom2, PG Ince2, M Azzouz2, J Xu*,1,5,
PJ Shaw2,5 and K Ning*,1,2,5
Excitatory transmission in the brain is commonly mediated by the a-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid
(AMPA) receptors. In amyotrophic lateral sclerosis (ALS), AMPA receptors allow cytotoxic levels of calcium into neurons,
contributing to motor neuron injury. We have previously shown that oculomotor neurons resistant to the disease process in ALS
show reduced AMPA-mediated inward calcium currents compared with vulnerable spinal motor neurons. We have also shown
that PTEN (phosphatase and tensin homolog deleted on chromosome 10) knockdown via siRNA promotes motor neuron survival
in models of spinal muscular atrophy (SMA) and ALS. It has been reported that inhibition of PTEN attenuates the death of
hippocampal neurons post injury by decreasing the effective translocation of the GluR2 subunit into the membrane. In addition,
leptin can regulate AMPA receptor trafficking via PTEN inhibition. Thus, we speculate that manipulation of AMPA receptors by
PTEN may represent a potential therapeutic strategy for neuroprotective intervention in ALS and other neurodegenerative
disorders. To this end, the first step is to establish a fibroblast–iPS–motor neuron in vitro cell model to study AMPA receptor
manipulation. Here we report that iPS-derived motor neurons from human fibroblasts express AMPA receptors. PTEN depletion
decreases AMPA receptor expression and AMPA-mediated whole-cell currents, resulting in inhibition of AMPA-induced neuronal
death in primary cultured and iPS-derived motor neurons. Taken together, our results imply that PTEN depletion may protect
motor neurons by inhibition of excitatory transmission that represents a therapeutic strategy of potential benefit for the
amelioration of excitotoxicity in ALS and other neurodegenerative disorders.
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Amyotrophic lateral sclerosis (ALS) is a devastating neuro-
degenerative disorder affecting upper and lower motor neurons
(MNs) and leading to death within 2–3 years from diagnosis.
Between 90 and 95% of cases are sporadic in origin, whereas
the remaining 5–10% of cases are familial. Of these, B20%
carry mutations in the gene encoding the superoxide dismutase
1 enzyme (SOD1).1 Transgenic mice expressing mutant forms
of human SOD1 are used as a model of familial ALS.2 We have
defined the gene expression profiles of MNs isolated from the
spinal cord of G93ASOD1 transgenic mice at different stages of
disease, by combining the use of laser capture microdissection
(LCM) and microarray technology. This work highlighted the
involvement of metabolism in the first stages of disease, along
with a substantial upregulation of transcription-related tran-
scripts.3 Metabolic impairment suggested that astrocytes
might also play a crucial role in the first stages of disease,
supporting the results from other groups.4–6
Hexanucleotide GGGGCC intronic expansions in the newly
identified C9ORF72 (chromosome 9 open reading frame 72)
gene represents the most common cause of both familial and
sporadic ALS,7,8 responsible for up to 50% of familial ALS and
B10% of sporadic ALS, but to date SOD1 mutations have
been the genetic subtype most widely studied and utilized to
model ALS. In the presence of mutant SOD1, multiple
interacting factors contribute to MN injury including protein
misfolding and aggregation, defective axonal transport,
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excitotoxicity, mitochondrial dysfunction, dysregulated tran-
scription and RNA processing, endoplasmic reticulum stress,
apoptosis, oxidative stress as well as toxicity caused by
nonneuronal cells.9 Of these mechanisms, excitotoxicity is
considered to play a key role. Routine excitatory transmission
in the brain is predominantly mediated by a-amino-3-hydroxy-
5-methyl-4-isoxazole propionic acid (AMPA) receptors. In
ALS, there is a body of evidence that excitotoxicity mediated
by calcium-permeable AMPA receptors contributes signifi-
cantly to MN injury. Riluzole, an antiexcitotoxic agent, is the
only drug proven to slow the disease progression in
humans.10 AMPA receptors have been proposed to play a
major role in the selective death of MNs in ALS. These
characteristics are related to the way MNs handle Ca2þ . MNs
have a low Ca2þ -buffering capacity and a high number of
Ca2þ -permeable AMPA receptors. A significantly different
ratio between inhibitory and excitatory synapses was present
in SOD1G93A mouse spinal cord slice cultures. SOD1G93A
MNs exhibited increased vulnerability to AMPA glutamate
receptor-mediated excitotoxic stress before the onset of an
overt disease phenotype.11 The levels of the glutamate
receptor 2 (GluR2) AMPA subunit, which plays an important
role in the maintenance of calcium impermeability of AMPA
receptors, are decreased in spinal MNs before symptom
onset in conjunction with a modest increase of GluR3
expression in SOD1G93A mice.12 GluR2 is a subunit of the
AMPA receptor, and the adenosine for the Q/R site of its pre-
mRNA is converted to inosine (A-to-I conversion) by the action
of adenosine deaminase acting on RNA 2 (ADAR2). Failure of
A-to-I conversion at this site affects multiple AMPA receptor
properties, including the Ca2þ permeability of the receptor-
coupled ion channel. Inefficient GluR2 Q/R site editing is a
disease-specific molecular dysfunction reported in the MNs of
sporadic ALS patients.13
We have previously shown that oculomotor neurons
resistant to the disease process in ALS show reduced
AMPA-mediated inward calcium currents, and higher GABA-
mediated chloride currents, compared with spinal MNs that
are vulnerable to the disease process.14 We have also
demonstrated that knockdown of phosphatase and tensin
homolog deleted on chromosome 10 (PTEN) via siRNA
promotes MN survival in models of spinal muscular atrophy
(SMA)15 and ALS.16 Inhibition of PTEN attenuates the death
of hippocampal neurons post injury by decreasing the
effective translocation of the GluR2 subunit into the mem-
brane.17 Leptin promotes GluR1 trafficking to hippocampal
synapses via PTEN inhibition.18 Furthermore, PI3-kinase that
is negatively regulated by PTEN is required for maintaining
AMPA receptor clustering at the postsynaptic mem-
branes19,20 and AMPA receptor surface expression.21 Thus,
we speculate that manipulation of AMPA receptor expression
and function by PTEN may represent a potential therapeutic
strategy for clinical intervention in ALS. The breakthrough that
human fibroblasts can be transformed into induced pluripotent
stem (iPS) cells22 and these could then be differentiated into
MNs23 opened new perspectives, providing a model of human
origin for sporadic and familial cases of ALS. The aim of the
present study is to establish a fibroblast-derived iPS-MN
in vitro cell model for manipulation of AMPA receptor
expression and function.
Results
Generation and characterization of human iPSCs
(hiPSCs) from adult human dermal fibroblasts (HDFs).
Under human research subject and stem cell protocols as
approved by the institutional review boards, we recruited a
healthy 40-year-old Chinese female to donate a skin biopsy
to be used in reprogramming studies and the production of
pluripotent stem cell lines. Three other healthy controls were
also used to generate induced pluripotent stem cells (iPSCs)
under ethical approval in the United Kingdom. The HDFs
were isolated and plated under standard fibroblast conditions
(Figure 1a). After four passages, the fibroblast identity in the
resulting cell lines was confirmed by TE-7 antibody staining
(Figure 1b). The cells were then used for generating iPS cells
after infection with retroviruses containing human OCT3/4,
SOX2, C-MYC and KLF4. As a control, we introduced green
fluorescent protein (GFP) into HDF with pMXs-GFP retro-
virus produced in PLAT-A packaging cells. More than 80% of
HDF treated in this way expressed GFP (Figure 1c). Using
this method, the dish was nearly covered with 4100
granulated colonies B25 days later. We observed distinct
types of colonies that were flat and resembled hES cell-like
colonies in between the granulated cells. At day 30, we
picked 20 hES cell-like colonies and mechanically disaggre-
gated them into small clumps without enzymatic digestion.
The hES-like cells expanded on irradiated mouse embryonic
fibroblasts (MEFs) using primate ES cell medium containing
fibroblast growth factor-basic (bFGF).
To establish that reprogramming of the human fibroblasts
had occurred, and that the putative hiPSCs were pluripotent,
we evaluated their similarity to human embryonic stem cells
(hESCs). Although we initially isolated 20 hiPSC clones, we
focused on an in-depth characterization of only one of these
clones. As illustrated in Figure 1d, the derived cells displayed
the morphological characteristics of undifferentiated hESCs
(i.e., large, compact, multicellular colonies of cells with a high
nucleus-to-cytoplasm ratio) and showed high telomerase
activity (Figures 1e and f). Moreover, they expressed several
frequently used hESC markers (i.e., OCT3/4, SOX2, LIN28,
NANOG, REX1) as shown by immunohistochemistry
(Figure 1g) and reverse transcription-PCR (RT-PCR;
Figure 1h). In addition, the putative hiPSC line also
maintained a normal karyotype (Figure 1i). The colonies
continued to passage after at least 6 months by passaging
once a week. The split ratio was 1 : 3 to 1 : 6. Bisulfite genomic
sequencing analyses evaluating the methylation status of
cytosine guanine dinucleotides (CpG) in the promoter region
of the pluripotent-associated gene Oct4 revealed that this was
highly unmethylated, whereas the CpG dinucleotides of the
region were highly methylated in parental HDF (Figure 1j).
These findings indicate that this promoter is active in hiPSCs.
To test pluripotency in vivo, we transplanted human
iPS cells subcutaneously into the hind limb muscle of
NOD/SCID mouse. At 8 weeks after injection, we observed
tumor formation. Histological examination showed that
the tumor contained various tissues: neural tissues
(ectoderm, Figure 1k), cartilage (mesoderm, Figure 1l),
muscle (mesoderm, Figure 1m) and primitive gut (endoderm,
Figure 1n).
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Taken together, these data demonstrate that reprogram-
ming of wild-type fibroblasts to a pluripotent state had
successfully occurred.
MN differentiation of hiPSCs. Several groups have
devised protocols to differentiate hESCs/hiPSCs to func-
tional MNs.23–25 Here we chose a protocol that follows the
principles of normal development and leads to a high
efficiency in the production of the target MNs (Figure 2a).
We raised hiPSCs in co-culture with a MEF feeder layer, as
previously described. The cultures were raised to 80–90%
confluence and exhibited a uniform undifferentiated pheno-
type to achieve neuro-ectodermalization before inducing
them to form embryoid bodies (EBs) in suspension cultures.
EB aggregates are usually grown as free-floating spheres.
The EBs were cultured for 7 days and then they were
attached to tissue culture dishes to initiate the differentiation
of neuroepithelial cells that soon emerge as neural epithelial
rosettes. After 3 days, the primitive neural epithelial cells
formed and expressed anterior transcription factors, such as
PAX6 and OTX2 (Figure 2b). After an additional 5 days in the
presence of retinoic acid (RA), definitive neuroepithelial cells
tended to form neural tube-like rosettes. The neural rosettes
were gently blown off and treated with both RA and sonic
hedgehog (SHH), resulting in the appearance of MN
progenitors. These cells then differentiated to spinal MNs in
week 5 and expressed transcription factors, such as Islet1/2
(Figure 2c). This protocol generated B50% of Islet1/2-
expressing MNs from the original hWT-iPSC cells. These
MNs, when further cultured in the presence of neurotrophic
factors, extend long axonal projections, express choline
acetyltransferase (ChAT; Figure 2d) and become electro-
physiologically active.
PTEN knockdown increases phosphorylation of Akt and
Bad in primary cultured MNs and iPS-derived MNs. The
tumor suppressor protein PTEN is a member of the protein
tyrosine phosphatase family that can negatively regulate the
serine/threonine kinase Akt to exert its tumor suppressor
function.26 The protein phosphatase activity of PTEN can
regulate cell migration, spreading and growth.27 PTEN is
widely expressed in the mouse CNS and preferentially in
neurons such as large pyramidal neurons.28 PTEN localizes
to both the nucleus and cytoplasm of neuronal and glial
cells.28–30 Significant progress has been made in investigat-
ing the broader role of PTEN in the brain. In addition to its
normal functions such as control of neuronal migration31,32
and neuronal size,33,34 the PTEN protein is involved in
pathological processes surrounding neuronal injury such as
those associated with brain ischemia, neurological and
mental disorders and drug addiction.33–39 Conditional inacti-
vation of PTEN leads to behavioral abnormalities and
neuropathological changes characterized by neuronal
hypertrophy.39 Park et al.40 reported that modulation of the
Figure 1 Characterization of human dermal fibroblasts used for hiPSC induction. (a) Culture of human dermal fibroblasts (bar¼ 50mm). (b) TE-7 immunostaining
confirmed that the resulting cultures were of fibroblast identity (bar¼ 100mm). (c) Phase contrast image of human dermal fibroblasts transfected with GFP retroviruses
(bar¼ 100mm). (d) The hESC-like hiPS colony (bar¼ 50mm). (e and f) These hESC-like colonies showed high alkaline phosphatase expression (bar¼ 50mm).
(g) Immunocytofluorescence of the hiPSCs showing the expression of multiple hESC markers (bar¼ 100mm). (h) RT-PCR analysis of hESC marker genes in hiPSCs.
(i) No karyotypic abnormalities were observed in the hiPSCs. (j) Open circles indicate unmethylated CpG dinucleotides, whereas closed circles indicate methylated CpGs in
the promotor of Oct4. After transplantation into the hind limb muscle of NOD/SCID mice, hiPSCs generated teratomas showing (k) neural tissue (ectoderm; bar¼ 100mm),
(l) cartilage (mesoderm; bar¼ 100 mm), (m) muscle (mesoderm; bar¼ 100mm) and (n) primitive gut (endoderm; bar¼ 100mm)
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PTEN/mTOR pathway promotes axon regeneration in the
adult CNS. To assess whether PTEN can be manipulated
in iPS-derived MNs, PTEN was suppressed via siRNA in
primary cultured and iPS-derived MNs. This resulted in
decreased PTEN expression as assessed by immunofluor-
escence staining (Figures 3a and e) and western blotting
(Figures 3b and f). Phosphorylation of Akt and Bad was
increased following PTEN knockdown (Figures 3c, d, g and h).
Figure 2 Generation and characterization of spinal motor neurons from hiPSCs. (a) Schematic drawing of the experimental setup and strategy to derive induced spinal
motor neurons. (b) When differentiated for 12 days, the hiPSC-derived primitive neuroepithelial cells are positive for OTX2 (red) and PAX6 (green), bar¼ 25mm. (c) When
differentiated for 35 days, the hiPSC-derived motor neurons are positive for Islet 1/2 (red), bar¼ 50mm. (d) When differentiated for 45 days, hiPSC-derived motor neurons
become mature, and are positive for ChAT (green), bar¼ 50mm. DAPI shown as blue denotes DAPI-stained nuclei
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This is consistent with our previous report15 in primary
cultured wild-type and SMA MNs.
PTEN knockdown decreases AMPA receptor expression
in primary cultured and iPS-derived MNs. The selective
vulnerability of MNs to AMPA receptor-mediated excitotoxi-
city can be studied in vitro using purified MNs. These MNs
are sensitive to AMPA- or kainate-induced excitotoxicity.41
AMPA- or kainate-induced MN death can be inhibited by
NBQX, an AMPA receptor antagonist.42 In this study, we
investigate the potential effects of PTEN on MN excitability in
primary cultured and iPS-derived MNs. The first step was to
assess whether PTEN knockdown has an effect on AMPA
receptor expression. Here we showed that PTEN knockdown
decreased GluR1 and GluR2 expression in primary cultured
MNs (Figures 4a–c) and iPS-derived MNs (Figures 4g–j).
GluR3 was decreased in iPS-derived MNs (Figure 4k), but
not in primary cultured MNs (Figure 4e). There was no
significant change in GluR4 expression in primary cultured
MNs (Figure 4f) or iPS-derived MNs (Figure 4l) at 7 days post
viral transfection.
PTEN knockdown decreases AMPA-induced whole-cell
currents in primary cultured and iPS-derived MNs.
Based on the decrease of expression of AMPA receptors
following PTEN silencing, we next tested the effects of
PTEN knockdown on the functional output of AMPA
receptors in primary cultured and iPS-derived MNs.
Whole-cell patch-clamp recording was performed to examine
the effects of PTEN knockdown on the electrophysiological
properties of primary cultured and iPS-derived MNs. Dose
responses of AMPA-induced whole-cell currents were
recorded in 20 mM extracellular Naþ at  60 mV, in
response to AMPA concentrations ranging from 5 mM to
5 mM. Each point represents mean±S.E.M. from three
cells. Average peak amplitudes were 24±6 pA (5 mM),
295±63 pA (50 mM), 422±58 pA (500 mM ) and 399±34 pA
(5 mM) in control primary cultured MNs; 28±3 pA (5 mM),
298±35 pA (50 mM), 362±50 pA (500 mM) and 404±34 pA
(5 mM), respectively, in scramble siPTEN primary cultured
MNs; 12±3 pA (5 mM), 138±41 pA (50 mM), 227±53 pA
(500 mM) and 278±32 pA (5 mM), respectively, in siPTEN
primary cultured MNs. PTEN knockdown decreases AMPA-
induced whole-cell currents in primary cultured MNs in
a dose-dependent manner (n¼ 3, *Po0.05, **Po0.01,
tested by one-way ANOVA). Similarly, average peak
amplitudes were 25±7 pA (5 mM), 272±58 pA (50 mM),
359±58 pA (500 mM) and 389±22 pA (5 mM), respectively,
in control iPS-derived MNs; 22±8 pA (5 mM), 267±49 pA
(50 mM), 352±55 pA (500 mM) and 402±76 pA (5 mM),
respectively, in scramble siPTEN iPS-derived MNs;
13±3 pA (5mM), 130±38 pA (50 mM), 237±26 pA (500 mM)
and 262±42 pA (5 mM), respectively, in siPTEN iPS-derived
MNs. PTEN knockdown decreases AMPA-induced whole-
cell currents in iPS-derived MNs in a dose-dependent
manner (n¼ 3, *Po0.05, **Po0.01, tested by one-way
Figure 3 PTEN knockdown (b and f) increases phosphorylation of AKT (c and g) and Bad (d and h) in primary cultured motor neurons and iPS-derived motor neurons.
Primary (a) or iPS-derived (e) motor neurons were immunostained with anti-tubulin (green), Hoechst (nuclear staining in blue) and PTEN (red). Scale bar, 20 mm. Western
blotting on homogenates from primary cultured (b–d) and iPS-derived motor neurons. PTEN is normalized by GAPDH (b and f) and pAKT is normalized by AKT (c and g).
pBAD is normalized by BAD (d and h). Results represent the meanþS.E.M. from four independent experiments. **Po0.01, tested by one-way ANOVA
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ANOVA). The EC50 values estimated from fits to pooled data
were 106mM for primary cultured MNs and 113mM for iPS-
derived MNs (Figures 5d and h). Average peak AMPA-
induced whole-cell currents were recorded in Naþ -free
extracellular solution containing 50 mM Ca2þ at  60 mV in
primary cultured and iPS-derived MNs, evoked by AMPA
100mM (n¼ 8). AMPA at 100mM was close to the EC50 from
the dose-response recordings for primary cultured MNs
(Figure 5c) and iPS-derived MNs (Figure 5g). Topical
application with 100mM AMPA elicited a mean amplitude of
whole-cell current in control (431±156 pA (n¼ 8)), scramble
siPTEN (401±126 pA (n¼ 8)) and siPTEN (198±59 pA
(n¼ 8)), respectively, in primary cultured MNs and iPS-
derived MN control (471±82 pA (n¼ 8)), scramble siPTEN
(437±96 pA (n¼ 8)) and siPTEN (208±69 pA (n¼ 8)),
respectively. PTEN knockdown by siRNA significantly
decreased AMPA-induced whole-cell currents in primary
cultured and iPS-derived MNs (Po0.01).
PTEN knockdown decreases AMPA-induced cell death
in primary cultured and iPS-derived MNs. AMPA receptor
trafficking plays a role in regulating excitatory synaptic
strength and multiple growth factors, and hormones mod-
ulate this process.43 The effects of leptin on GluR1 trafficking
involve an increase in PtdIns(3,4,5)P3 levels secondary to
PTEN inhibition as the effects of leptin on surface GluR1
staining were associated with increased PtdIns(3,4,5)P3
levels and elevation in PtdIns(3,4,5)P3 levels occurred
before altered GluR1 trafficking. Inhibitors of PI3-kinase
attenuated the effects of leptin on surface GluR1 and
Figure 4 PTEN knockdown decreases AMPA receptor expression in primary cultured (a–f) and iPS-derived (g–l) motor neurons. Motor neurons were immunostained with
anti-tubulin (green), Hoechst (nuclear staining in blue) and AMPA receptor (GluR1, red). Scale bar, 20 mm. (b–f and h–l) Western blotting. PTEN knockdown decreases GluR1
(c and i) and GluR2 (d and j) but not GluR4 expression in both primary cultured and iPS-derived MNs. GluR3 decreases significantly in iPS-derived MNs (k) but not in primary
cultured MNs (e). Results represent the meanþS.E.M. from four independent experiments. **Po0.01, tested by one-way ANOVA
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PtdIns(3,4,5)P3 levels, consistent with PI3-kinase-depen-
dent signaling underlying these effects.44 Alterations in
PtdIns(3,4,5)P3 levels may promote structural rearrange-
ment of the actin cytoskeleton that in turn influences the
synaptic density of AMPA receptors.45 MNs are thought to be
vulnerable to excessive AMPA receptor stimulation because
of the presence of a high number of GluR2-lacking AMPA
receptors. Low GluR2 levels yield AMPA receptors with a
high Caþ þ permeability.46–49 A downregulation of GluR2
expression preceding neurodegeneration has never been
observed. However, relatively low GluR2 expression is likely
to contribute to the selective vulnerability of MNs to AMPA
receptor stimulation. It has been recently reported that toxic
factors released from glial cells expressing mt SOD1
contribute to the MN toxicity.50,51 To determine whether
downregulation of AMPA receptor expression can contribute
to MN survival, we used the TUNEL (terminal deoxynucleo-
tidyl transferase dUTP nick end labeling) assay to assess
apoptotic cell death in primary cultured and iPS-derived MNs.
Cells were treated with 50, 100, 200, 300, 400, 500 and
600mM (S)-AMPA to determine dose-response effects of
AMPA exposure. In control primary cultured MNs,
5.1±1.6%, 8.1±2.3% (50 mM), 11.5±2.1% (100 mM),
21.0±3.7% (200 mM), 48.4±9.7% (300 mM), 59.1±9.7%
(400 mM), 66.6±12.5% (500 mM) and 70.5±8.7% (500 mM)
TUNEL-positive cells were seen, respectively. Exposure to
300 mM AMPA resulted in the death ofB50% of the MNs and
this was inhibited by the AMPA receptor inhibitor (cyano-7-
nitroquinoxaline-2,3-dione (CNQX; Figure 6). PTEN knock-
down significantly reduced cell death in primary cultured MNs
(control 48.8%, scramble 44.1% and siPTEN 25.2%,
respectively) and iPS-derived MNs (Control 50.5%, scramble
48.9% and siPTEN 27.9%, respectively) (Figure 6).
Discussion
The aim of the present study was to determine whether PTEN
knockdown has an effect on functional AMPA receptor
expression and AMPA-mediated cell death in primary cultured
and iPS-derived MNs. AMPA receptors are heteromeric
complexes composed of various combinations of the four
subunits: GLUR1 to GLUR4. The presence of the GLUR2
subunit in the assembled AMPAR determines its calcium
permeability, and alternative flip or flop splicing of all subunits
generates further diversity affecting the kinetic properties of
AMPAR.43,44 MNs are more susceptible to AMPA receptor-
mediated death compared with other spinal neurons.47,48
Deactivation and desensitization kinetics of AMPA receptors
Figure 5 PTEN knockdown decreases AMPA-induced whole-cell currents in primary cultured (a–d) and iPS-derived (e–h) motor neurons. Primary cultured (a) and iPS-
derived (e) motor neurons were immunostained with anti-tubulin (green), Hoechst (nuclear staining in blue) and ChAT (red). Scale bar, 20 mm. (b and f) Representative current
traces elicited by AMPA. (c and g) Dose response of AMPA-induced whole-cell currents were recorded in 20mM extracellular Naþ at  60mV, in response to AMPA
concentrations ranging from 5 mM to 5mM. Each point represents the mean±S.E.M. from three cells (*Po0.05, **Po0.01, tested by one-way ANOVA). EC50 values
estimated from fits to pooled data were 106 mM for primary cultured motor neurons and 113mM for iPS-derived neurons. (d and h) Average peak AMPA-induced whole-cell
currents were recorded in Naþ -free extracellular solution containing 50mM Ca2þ at  60mV in primary cultured and iPS-derived motor neurons, evoked by AMPA 100mM
(n¼ 8). Columns represent the peak amplitudes of agonist-induced whole-cell currents. Results represent the meanþ S.E.M. from four independent experiments, with
8 motor neurons of each (*Po0.05, **Po0.01, tested by one-way ANOVA)
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in MNs also resembled AMPA receptor kinetics in cerebellar
Purkinje neurons.47 Activation of PI3-kinase is required for
AMPA receptor insertion during long-term potentiation (LTP)
of mEPSCs in cultured hippocampal neurons.44 Although the
molecular control of AMPA receptor kinetics is complex and
incompletely understood, subunit composition appears to be
an important determinant of AMPA receptor desensitization.52
To assess functional AMPA receptors in primary cultured
and iPS-derived MNs, we measured AMPA receptor-
mediated current in both types of cells. PTEN knockdown
decreased GluR1 and GluR2 expression and AMPA-induced
whole-cell currents. Downregulation of GluR1 was more
significant than of GluR2. Our findings appear to imply that
the ratio of GluR1 and GluR2 changes following PTEN
knockdown may cause variation in the AMPA receptor
properies of calcium permeability and excitatory synaptic
transmission. It has been reported that the antiglutamate
drug, riluzole, is able to modulate AMPA receptors by
reducing the kainate-induced currents in spinal MNs in a
noncompetitive and a dose-dependent manner. AMPA is
considered to play an important role in the selective death of
MNs in ALS. A significantly different ratio between inhibitory
and excitatory synapses was present in MNs from the
SOD1G93A mouse.11 The levels of the GluR2 AMPA subunit
are decreased in spinal MNs before symptom onset in
SOD1G93A mice.12 Inefficient GluR2 Q/R site editing appears
to be a disease-specific molecular alteration reported in
sporadic ALS patients.13 At the level of the glutamatergic
synapse, high concentrations of riluzole have been reported to
inhibit glutamate release, attenuate excitatory amino acid
receptor activation and decrease excitability of the postsy-
naptic cell membrane.52 The high concentrations required,
however, are unlikely to be reached in vivo using clinically
approved doses. AMPA receptors are glutamate-gated cation
selective channels that mediate most fast excitatory synaptic
transmission in the mammalian brain. AMPA receptor
desensitization protects neurons against excitotoxic effects
resulting from prolonged activation, as suggested by the
pharmacological blockade of AMPAR desensitization that
enhances excitotoxicity in neurons, including spinal
MNs.10,46–49,52 Here we report that PTEN inhibition decreases
AMPA-induced cell death in primary cultured and iPS-derived
MNs by downregulation of AMPA receptor expression and
function assessed by AMPA-mediated whole-cell currents.
We have previously reported that oculomotor neurons
resistant to the disease process in ALS show reduced AMPA-
mediated inward calcium current compared with spinal MNs
that are vulnerable to the disease process.10 These data
implied that downregulation of AMPA receptor expression in
spinal MNs might increase their resistance to exctitotoxic
injury. We previously showed that PTEN depletion increased
MN survival in models of SMA and ALS.15,16 Here we show
that PTEN inhibition decreases AMPA-mediated inward
currents. Thus, PTEN depletion or inactivation may represent
Figure 6 PTEN knockdown decreases AMPA-induced cell death in primary cultured and iPS-derived motor neurons. Primary cultured (a) and iPS-derived (c) motor
neurons were immunostained with anti-tubulin (green), Hoechst (nuclear staining in blue) and TUNEL staining (red). Scale bar, 20 mm. (b and d) Results represent the
meanþ S.E.M. from four independent experiments. **Po0.01, tested by one-way ANOVA
PTEN regulates AMPA receptor-mediated cell viability
D-J Yang et al
8
Cell Death and Disease
a therapeutic or neuroprotective strategy for AMPA receptor-
mediated MN death.
It has been reported that reduction of kainate-induced
currents by riluzole is consistent with its neuroprotective
effects, because it hyperpolarizes the membrane and
attenuates spike-firing rates, leading to reduced presynaptic
glutamate release. However, riluzole has a limited effect in the
clinical setting because the high concentrations required to
achieve these effects are unlikely to be reached in vivo using
clinically approved doses.53 PTEN silencing may achieve
amelioration of AMPA receptor-mediated toxicity in vivo.
Indeed, PTEN depletion has been shown to dramatically
increase MN survival in vivo.15
We have observed that the results obtained from iPS-derived
and primary cultured MNs are mostly but not always consistent;
for example, GluR3 decreases significantly in iPS-derived MNs
(Figure 4k) but not in primary cultured MNs (Figure 4e). We
used the best PTEN shRNA sequence from multiple tested
sequences for the lentiviral constructs for the transduction of
primary MNs. This siRNA has been tested in neuronal cell
lines38,54 and MNs in vitro16 and in vivo.15 The PTEN siRNA
virus we used for iPS-derived MNs was purchased from Santa
Cruz Biotechnology Inc. (Dallas, TX, USA), which has been
fully characterized by the company, and its efficiency of PTEN
knockdown has been tested widely by various research
groups.55,56 As both the cells and the siRNA virus are different,
it would be possible to have variation for GluR3 knockdown
between primary cultured and iPS-derived MNs. This differ-
ence is unlikely to represent off-target effects. We have not
seen significant PTEN knockdown using scrambled siRNA
sequences and other siRNA sequences.15,16,54–56 We believe
therefore that the PTEN knockdown is specific in both primary
cultured and iPS-derived MNs.
In conclusion, we have shown for the first time that PTEN
knockdown decreases the expression and activity of AMPA
receptors in MNs. Modulation of AMPA receptors may
underlie some of the neuroprotective effects of PTEN
inhibition or reduced expression of the PTEN protein. In
future work, we will use ALS patient fibroblasts to generate
iPS-derived MNs and investigate the effect of PTEN knock-
down on MN survival in patient iPS-derived MNs from specific
subtypes of ALS patients. This may represent a useful
strategy for drug screening to identify compounds that may
modulate disorders involving neuronal hyperexcitability,
including ALS.
Materials and Methods
Human fibroblast and Plat-A culture. Under human research subject
and stem cell protocols as approved by the institutional review boards, we
recruited a healthy 40-year-old Chinese female to donate a skin biopsy to be used
in reprogramming studies and the production of pluripotent stem cell lines. Three
other healthy controls were also used to generate iPSCs under ethical approval in
the United Kingdom. The dermal fibroblasts were isolated by 0.25% trypsin (Gibco,
Shanghai, China, 25200). HDFs and Plat-A cells were maintained in medium
containing Dulbecco’s modified Eagle’s medium (DMEM; Gibco, 11965-092), 10%
fetal bovine serum (FBS, Thermo, Shanghai, China), 1% nonessential amino acids
(NEAA, Gibco, 11140-050) and 1% GlutaMAX (Gibco, 35050).
Generation of hiPSCs from adult HDFs. Plat-A packaging cells were
plated at 6 106 cells per 100mm dish and incubated overnight. After 1 day, the
cells were transfected with retroviral vector pMXs (encoding Oct4, Sox2, Klf4 and
c-Myc) using Lipofectamine 2000 transfection reagent (Gibco, GB11668-019).
At 48 h after transfection, the medium was collected as the first virus-containing
supernatant and replaced with new medium that was collected 24 h later as the
second virus-containing supernatant. The virus-containing supernatants were filtered
through a 0.45mm pore-size filter and supplemented with 10mg/ml polybrene
(Sigma, St. Louis, MO, USA, H9268). Equal amounts of virus-containing
supernatants containing each of the four retroviruses were mixed before
transduction, transferred to the fibroblast dish and incubated overnight.
Approximately 50 000 fibroblasts per well of a six-well plate were transduced twice
over 48 h. Then, the transduced cells were passaged on plates containing irradiated
MEFs. The medium was replaced with iPSCs medium, containing DMEM/F12
(Gibco, 11330), 20% knockout serum replacement (KSR, Gibco, 10828-028), 1%
nonessential amino acids (NEAA, Gibco, 11140-050), 1% GlutaMAX (Gibco, 35050),
0.1mM b-mercaptoethanol (Sigma) and 4 ng/ml bFGF (R&D, St. Louis, MO, USA).
The first hiPSC colonies appearedB2 weeks later and they could be picked after
1–2 additional weeks of culture. Individual colonies were picked and either
transferred into a single well of 12-well plates containing iPSC medium and
irradiated MEFs. For passaging, hiPSCs were incubated with DMEM/F12 containing
collagenase IV (1mg/ml) at 371C for 10–15min. When colonies at the edge of the
dish were dissociating from the bottom, the enzyme was removed and washed by
iPSC medium without bFGF. Cells were collected by gently pipetting.
RNA isolation and PCR analysis. Total RNA was isolated using the
RNAsimple Total RNA Kit (Tiangen, Shanghai, China). Total RNA at 1 mg was
used for the reverse transcription reaction with the RevertAid First Strand cDNA
synthesis kit (Fermentas, Beijing, China). The cDNA from MEFs was used as a
negative control, whereas that from hESCs was used as a positive control.
RT-PCR was performed using specific sequences:57 hOCT3/4-F 50-GACAGG
GGGAGGGGAGGAGCTAGG-30, hOCT3/4-R 50-CTTCCCTCCAACCAGTTGCCC
CAAAC-30; hSOX2-F 50-GGGAAATGGGAGGGGTGCAAAAGAGG-30, hSOX2-R
50-TTGCGTGAGTGTGGATGGGATTGGTG-30; hKLF4-F 50-AGAAGCGACAG
AATCAAA-30, hKLF4-R 50-GGACCTGGTATGTGGAGA-30; hc-MYC-F 50-GCG
TCCTGGGAAGGGAGATCCGGAGC-30, hc-MYC-R 50-TTGAGGGGCATCGTCG
CGGGAGGCTG-30; hNANOG-F 50-ACCAGGCACTACCGTAAACA-30, hNANOG-R
50-CCCTCATCGGGAAGACAG-30; hLIN28-F 50-GGATGTCTTTGTGCACCAGA-30,
hLIN28-R 50-CTCCTTTTGATCTGCGCTTC-30; REX1-F 50-CAGATCCTAAACAG
CTCGCAGAAT-30, REX1-R 50-GCGTACGCAAATTAAAGTCCAGA-30; hGAPD
H-F 50-CAAGATCATCAGCAATGCCTCCTG-30, hGAPDH-R 50-GCCTGCTTCAC
CACCTTCTTGA-30.
Alkaline phosphatase staining and immunocytochemistry. Alka-
line phosphatase staining was performed using the Alkaline Phosphatase
Detection kit (Si Dan Sai, Shanghai, China, 1102). For immunocytochemistry, cells
were fixed with phosphate-buffered saline (PBS) containing 4% paraformaldehyde
(PFA) for 10min at room temperature. After washing with PBS, the cells were
treated with PBS containing 4% normal donkey serum (Jackson Immuno-
Research, West Grove, PA, USA, 017-000-121), 1% bovine serum albumin (BSA,
Sigma) and 0.1% Triton X-100 for 45min at room temperature. Primary antibodies
included SSEA3 (1 : 100, Invitrogen, Paisley, UK), SSEA4 (1 : 100, Invitrogen),
TRA-1-60 (1 : 200, Millipore, Billerica, MA, USA), TRA-1-81 (1 : 200, Millipore),
OCT3/4 (1 : 100, Santa Cruz Biotechnology, Inc.), SOX2 (1 : 200, Millipore), TE-7
(1 : 200, Chemicon, Billerica, MA, USA), rabbit polyclonal antibodies against
tubulin (1 : 500, Cell Signaling, Danvers, MA, USA), mouse monoclonal antibodies
against tubulin (1 : 500, Millipore), rabbit monoclonal antibodies against PTEN
(1 : 100, Cell Signaling), anti-glutamate receptor 1 (AMPA subtype) (1 : 100,
Abcam, Cambridge, UK) and ChAT (1 : 100, Abcam). Secondary antibodies used
were CF488A-conjugated donkey anti-goat IgG (1 : 800, Biotium, Hayward, CA,
USA), CF488A-conjugated donkey anti-rat IgG (1 : 800, Biotium), CF488A-
conjugated donkey anti-mouse IgG (1 : 800, Biotium), CF488A-conjugated donkey
anti-rabbit IgG (1 : 800, Biotium), Cy3-conjugated donkey anti-rabbit and FITC-
conjugated donkey anti mouse (1 : 300, Cell Signaling) and incubated at 41C
overnight. Cells were then washed three times with 1 PBS. Mounted MNs were
viewed using a Leica (Wetzlar, Germany) TCS SP5 confocal microscope.
Teratoma formation. One million hWT-iPSCs cells were injected subcuta-
neously into the hind limb muscle of the NOD/SCID mouse (Jackson Laboratory,
Bar Harbor, ME, USA). Paraffin sections of formalin-fixed teratoma specimens
were prepared 6–8 weeks after injection, and analysis of H&E-stained tissue
sections was performed for each specimen. All animal experiments were
performed in accordance with the institutional guidelines.
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Bisulfite sequencing and karyotype analysis. Bisulfite treatment was
performed using the EZ DNA Methylation-gold kit (ZYMO Research, Irvine, CA, USA),
according to the manufacturer’s recommendations. PCR primers are: out-forward,
50-GTTAAGGTTAGTGGGTGGGATT-30; out-reverse, 50-ATCACCTCCACCACCTAA
AAA-30; in-forward, 50-AGAGAGGGGTTGAGTAGTTTTTT-30; in-reverse, 50-ACCT
CCACCACCTAAAAAAAAC-30. Amplified products were cloned into pMD18-T
Vector (Takara, Shiga, Japan). Ten randomly selected clones were sequenced
with the M13 forward and M13 reverse primers for each gene. Chromosomal
G-band analyses were performed at Tongji Hospital, (Shanghai, China).
Viral vectors. A 19-nt sequence targeting mouse PTEN was subcloned in the
pLVTHM genome vector (Addgene plasmid 12247, Cambridge, MA, USA) as
previously described.15 Briefly, siPTEN sense oligonucleotide 50-CGCGTCCCCGC
CAAATTTAACTGCAGAGTTCAAGAGACTCTGCAGTTAAATTTGGCTTTTTGGA
AAT and siPTEN antisense oligonucleotide 50-CGATTTCCAAAAAGCCAAATT
TAACTGCAGAGTCTCTTGAACTCTGCAGTTAAATTTGGCGGGGA were annealed
and cloned into the MluI/ClaI-digested vector. Accordingly, scrambled siPTEN sense
nucleotide 50-CGCGTCCCCCGCAATATTCAATCGAGGATTCAAGAGATCCTCGA
TTGAATATTGCGTTTTTGGAAAT and ssiPTEN antisense nucleotide 50-CGATTTC
CAAAAACGCAATATTCAATCGAGGATCTCTTGAATCCTCGATTGAATATTGCGGGG
GA were used to generate the control LV-ssiPTEN vector. The third generation of
self-inactivating (SIN) lentiviral vector stocks involving four plasmids (pMD.2G,
pCMVDR8.92, SIN-W-PGK and pRSV-Rev) were prepared by transient calcium
phosphate transfection of the human embryonic kidney 293T cell line as previously
described.15,57 These vectors were pseudotyped with the vesicular stomatitis
virus-G envelope protein. Viral titers were estimated using a FACS assay.15 For
iPS-derived MNs, PTEN shRNA (h) Lentiviral vector containing three target-
specific constructs that encode 19–25 nt (plus hairpin) shRNA designed to target
human PTEN were purchased from Santa Cruz Biotechnology (sc-29459 and
control shRNA Lentiviral Particles: sc-108080).
MN culture. Cultures of embryonic spinal MNs were prepared as previously
described.15 Briefly, the ventrolateral part of the E13 spinal cord was dissected
and incubated at 371C for 15min in 0.1% trypsin in Hanks’ balanced salt solution.
After trituration, cells were plated on dishes precoated with anti-p75 nerve growth
factor (NGF) receptor antibody (Abcam, ME20.4, ab8877) in Neurobasal (Gibco)
for 30min. The cells were washed three times with Neurobasal, and the attached
cells were isolated from the plate with depolarizing solution (0.8% NaCl, 35mM
KCl) and collected in full media (Neurobasal supplemented with 2% horse serum,
2% B27 (Gibco), 0.1 mM b-mercaptoethanol (Sigma) and 1 Glutamax (Gibco)).
For staining, 2000 cells were plated on poly-DL-ornithine (Sigma) and mouse
laminin (Invitrogen)-coated coverslips in four-well dishes (Greiner, Frickenhausen,
Germany). For western blots, 100 000 cells were plated on each well of 12-well
plate also coated with poly-ornithine and mouse laminin. MNs were transduced at
24 h after plating with multiplicity of infection (MOI) of 10. For all assays, brain-
derived neurotropic factor was used at concentrations of 5 ng/ml and MNs were
cultured at 371C with 5% CO2. Medium was replaced after 24 h and then every 2
days. AMPA treatment for survival (TUNEL assay) and electrophysiology were
carried out from day 7 onwards. Cells were treated with 50, 100, 200, 300, 400,
500 and 600mM (S)-AMPA to determine dose-response effects of AMPA
treatments. Of the neurons, 50% were TUNEL positive at 24 h following exposure
to 300mM AMPA for 1 h. For AMPA inhibition, 50mM CNQX (Sigma) was added
to culture medium 1 h before MNs were exposed to 300mM (S)-AMPA (Sigma) for
1 h and then fresh medium was applied for 24 h before performing a TUNEL
survival assay.58
The iPS-derived MN differentiation. The iPS cells were maintained on
gelatinized tissue-culture plastic in iPS media containing DMEM/F12 (Gibco,
11330), 20% knockout serum replacement (KSR, Gibco, 10828-028), 1% NEAA
(Gibco, 11140-050), 1% GlutaMAX (Gibco, 35050), 0.1 mM b-mercaptoethanol
(Sigma) and 4 ng/ml bFGF (R&D) at 371C, 5% CO2. Medium was changed every
24 h. To generate MNs,23–25 iPS cells were passaged using dispase (1 mg/ml) and
triturated into small cell clumps and placed into ultralow adherent culture dishes
(Corning, Corning, NY, USA). For the first 3 days, cells were kept in suspension in
iPS medium, to enhance single cell survival, and 20 ng/ml bFGF (Invitrogen) was
added to enhance growth. At day 4, EBs were switched to neural induction
medium (DMEM/F12 with L-glutamine; NEAA; penicillin/streptomycin; heparin,
2mg/ml; N2 supplement; Invitrogen). At day 6, all-trans retinoic acid (RA; 1mM;
Sigma) was added. The same medium was changed with fresh RA daily.
Hedgehog signaling was initiated on day 15 by application of SHH (100 ng/ml,
R&D) and purmorphamine (PUR, 1 mM). The same media was changed with
freshly daily. At day 28, basal medium was changed to Neurobasal (Invitrogen),
containing all previous factors, with the addition of 10 ng/ml of insulin-like growth
factor 1 (IGF-1) and 1 mM cAMP (Sigma). At day 35, EBs were dissociated with
0.05% trypsin (Invitrogen) and plated onto poly-lysine/laminin-coated dishes or
coverslips. Plated neurons were cultured in the same medium as above with
addition of ascorbic acid (200 ng, Sigma). Cells were transduced with human
shRNA PTEN lentiviral vectors with MOI of 10 for 7 days before assessment. Cells
were treated with 50, 100, 200, 300, 400, 500 and 600mM (S)-AMPA to determine
dose-response effects of AMPA treatment. Approximately 50% of the cells were
TUNEL positive 24 h after exposure to 300mM AMPA for 1 h. Exposure to AMPA
with assays for survival (TUNEL assay) and electrophysiology were carried out
from day 45 onwards. For AMPA inhibition, 50 mM CNQX (Sigma) was added to
culture medium 1 h before MNs were exposed to 300mM (S)-AMPA (Sigma) for
1 h and then fresh medium was applied for 24 h before performing a TUNEL
survival assay.58
Electrophysiology. Whole-cell electrophysiological experiments were
recorded as previously described.14 Voltage clamp recordings were performed
using an Axon Multi-Clamp 700B amplifier (Axon Instruments, Sunnyvale, CA,
USA) using unpolished borosilicate pipettes placed at the cell soma. Pipettes had
a resistance of 2–4MO when filled with intracellular solution. Intracellular solution
for AMPA- or kainate-induced currents consisted of 120mM CsF, 3 mM MgCl2,
5 mM EGTA and 10mM HEPES (pH adjusted to 7.25 with 12mM CsOH). Csþ in
the pipette solution was included to block Kþ -dependent membrane conductance.
Cells were accepted for study if a stable seal formed with a whole-cell resistance
of at least 120M O and a series resistance ofo10MO. Receptors were activated
by focal perfusion of agonists from a micropipette with its tip located 30–50mm
from the cell. Three cells were used for dose-response recordings for AMPA-
induced whole-cell currents. Currents were recorded in 20mM extracellular Naþ
at  60mV, in response to AMPA concentrations ranging from 5mM to 5mM. The
extracellular perfusion buffer consisted of 15.3mM NaCl, 4.7 mM NaOH, 2mM
CaCl2, 10mM HEPES, 10mM glucose and 228mM sucrose, pH 7.40. For the
measurement of Ca2þ permeability, 100mM AMPA, close to the EC50 from the
dose-response recordings, was used. All extracellular solutions were supplemen-
ted with MK- 801 (10mM), tetrodotoxin (1.0mM) and Cd2þ (100 mM) to block
NMDA receptors, voltage-gated Naþ channels and Ca2þ channels, respectively.
Cells were held at a membrane potential of  60mV. All recordings were
performed at room temperature of 21–231C. Current recordings were sampled
onto an IBM-PC compatible computer using pClamp10 software (Axon). Data
were filtered at 3 kHz and sampled at 20–40 kHz.
TUNEL staining. Primary cultured or iPS-induced neurons were stained by
the TUNEL technique (ApopTag@Red In Situ Apoptosis Detection Kit) according
to the manufacturer’s instructions (Millipore). MNs were fixed in 4% PFA in PBS at
room temperature for 15min. MNs were incubated in equilibration buffer for 1 h at
room temperature. The buffer was then removed and samples were incubated in
reaction buffer and TdT enzyme mix at 371C for 90min. The mix was then
replaced with the stop buffer. Samples were kept at 371C for 3 h. They were then
washed in PBT and incubated with gentle shaking in blocking solution and anti-
DIG-rhodamine mix overnight at 41C. After that, rabbit anti-tubulin primary
antibody (1 : 500; Cell Signaling) followed by CF488A-conjugated donkey anti-
rabbit IgG (1 : 800, Biotium) was stained in green as described in the
immunocytochemistry methods. Hoechst staining was used to stain nuclei in
blue. Mounted MNs were viewed using a Leica TCS SP5 confocal microscope.
Western blot analysis. Primary cultured or iPS-derived MNs were
transduced with lentiviral vectors for 7 days and collected from the dishes.
Protein extraction for western blotting was performed as described previously.15,16
Primary antibodies, anti-mouse glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) antibody (1 : 5000; Calbiochem, Darmstadt, Germany), tubulin
(1 : 5000; Millipore), anti-rabbit PTEN (1 : 1000; Cell Signaling), AKT (1 : 1000;
Cell Signaling), Bad (1 : 1000; Cell Signaling), pAKT ser473 (1 : 1000; Cell
Signaling), p-Bad ser155 (1 : 1000; Cell Signaling), Glutamate receptor 1 (AMPA
subtype) (1 : 1000; Abcam), Glutamate receptor 2 (AMPA subtype) (1 : 1000; Cell
Signaling), Glutamate receptor 3 (AMPA subtype) (1 : 1000; Cell Signaling),
Glutamate receptor 4 (AMPA subtype) (1 : 1000; Cell Signaling), goat anti-rabbit or
mouse HRP secondary antibodies (1 : 5000; Cell Signaling) were used.
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Statistical analysis. Power analysis was conducted using GPower 3.0
software (Oakland, CA, USA) and statistical analysis was performed using
GraphPad Prism v5 (La Jolla, CA, USA). Statistical significance was determined
by one-way analysis of variance (ANOVA) depending on the individual experiment
as stated in the figure legends.
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